2019 firm and individual rankings are now live
September 25, 2019
New content includes national firm rankings, life sciences stars and editorial reviews
US
Hatch-Waxman Patent Litigation (Branded)
| Hatch-Waxman Patent Litigation (Branded) — Highly Recommended |
|---|
| Covington & Burling |
| Finnegan Henderson Farabow Garrett & Dunner |
| Fish & Richardson |
| Paul Hastings |
| Sidley Austin |
| Venable |
| Williams & Connolly |
| WilmerHale |
| Hatch-Waxman Patent Litigation (Branded) — Recommended |
|---|
| Arnold & Porter |
| Bartlit Beck |
| Dechert |
| Jones Day |
| Kirkland & Ellis |
| Mayer Brown |
| O'Melveny & Myers |
| Quinn Emanuel Urquhart & Sullivan |
| Lawyer | Section | Practice Area | Location |
|---|---|---|---|
| Brody, Steve | Non-IP Litigation & Enforcement | White-Collar/Govt. Investigations, Product Liability | Washington, D.C. |
| Carter, Maggie | Non-IP Litigation & Enforcement | White-Collar/Govt. Investigations | Los Angeles |
| Goetz, Richard | Non-IP Litigation & Enforcement | Product Liability | Los Angeles |
| Kappos, John | Intellectual Property | General Patent Litigation | Newport Beach |
| Pensabene, Lisa | Intellectual Property | Hatch-Waxman Patent Litigation, Patent Strategy & Management, General Patent Litigation | New York City |
| Petrocelli, Daniel | Non-IP Litigation & Enforcement | Product Liability | Century City |
| Voelz, Scott | Non-IP Litigation & Enforcement | Product Liability | Los Angeles |
| , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} |
Intellectual Property
O'Melveny & Myers
O'Melveny & Myers is a new entrant to the IP rankings this year for its team focused on Hatch-Waxman litigation for branded drug companies. The firm acts for a number of major companies, including AstraZeneca, Amgen subsidiary Onyx Therapeutics and ViiV Healthcare. A peer calls the group a "terrific firm," while another notes O'Melveny's "very strategic and talented team."
New York-based Lisa Pensabene is the firm's life sciences litigation practice head, who brings significant expertise in pharmaceutical patent disputes. She recently acted for AstraZeneca in suits brought against several generic companies seeking to market versions of the client's Faslodex product. The last remaining case concluded in late 2018. For her continued work in this area, Pensabene was shortlisted for the Branded Hatch-Waxman Litigator of Year award by LMG Life Sciences.
John Kappos is another noteworthy litigator at the firm, bringing two decades of experience in law. He is currently acting for Agilent Technologies in a trade secrets suit brought against a competitor.
Non-IP Litigation & Enforcement
While O'Melveny & Myers is not a firm that fashions itself as a life sciences specialty shop, two of its biggest wins of the year have involved this industry, logged by two Los Angeles trial lawyers.
Celebrity courtroom ace Dan Petrocelli secured a complete defense verdict for Janssen Pharmaceuticals and Johnson & Johnson in the first bellwether trial in a California Coordinated Proceeding involving more than 10,000 claims over the antipsychotic medication Risperdal. The trial involved claims by a 24-year-old Kansas man that he developed gynecomastia from prior Risperdal use. The plaintiff was prescribed Risperdal "off-label" as a child, for severe violence and behavioral issues, before it was approved by the FDA for children. Petrocelli and the O'Melveny team also exposed that the plaintiff's claim had been manufactured after his mother saw an attorney advertisement on television and that the plaintiff did not even have gynecomastia; any enlargement of his breasts was due to fatty, rather than glandular, tissue. After a more than two-week trial, the jury rendered a verdict for the defense in less than two hours. Several more Risperdal cases are set for trial in 2018.
Richard Goetz is defending Amylin, a subsidiary of AstraZeneca, against claims brought by hundreds of plaintiffs in personal injury cases involving Byetta, an injectable medication for type-2 diabetes, in a California Coordinated Proceeding and a federal multidistrict litigation. The suits allege that Amylin failed to adequately test and monitor the side effects of the drug, and did not warn doctors or patients of the risk of developing pancreatic cancer, thyroid cancer and/or pancreatitis. The federal and state courts both granted summary judgment in the defendants' favor on preemption grounds, but the Ninth Circuit reversed to allow additional discovery, and the issues will then be briefed again. The state court order is on appeal.
Articles
New content includes national firm rankings, life sciences stars and editorial reviews